-$0.17 Earnings Per Share Expected for Amyris Inc (AMRS) This Quarter
Equities analysts forecast that Amyris Inc (NASDAQ:AMRS) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Amyris’ earnings, with estimates ranging from ($0.23) to ($0.11). Amyris posted earnings per share of ($1.14) during the same quarter last year, which would indicate a positive year over year growth rate of 85.1%. The firm is expected to issue its next earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Amyris will report full year earnings of ($1.41) per share for the current financial year, with EPS estimates ranging from ($1.56) to ($1.26). For the next fiscal year, analysts anticipate that the business will post earnings of $0.19 per share, with EPS estimates ranging from $0.16 to $0.22. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Amyris.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The firm had revenue of $24.81 million for the quarter, compared to analysts’ expectations of $37.52 million. During the same period in the previous year, the company earned ($1.32) EPS. The firm’s revenue for the quarter was down 3.4% on a year-over-year basis.
Shares of AMRS stock traded up $0.31 during trading hours on Thursday, reaching $8.32. The company had a trading volume of 71,276 shares, compared to its average volume of 1,103,656. Amyris has a one year low of $2.82 and a one year high of $9.22. The firm has a market capitalization of $400.43 million, a PE ratio of -2.72 and a beta of 0.18. The company has a quick ratio of 0.38, a current ratio of 0.42 and a debt-to-equity ratio of -0.24.
In other Amyris news, Director Patrick Y. Yang bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 9th. The stock was bought at an average cost of $7.71 per share, for a total transaction of $77,100.00. Following the completion of the transaction, the director now owns 36,932 shares of the company’s stock, valued at approximately $284,745.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Melo sold 22,355 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $6.61, for a total transaction of $147,766.55. Following the sale, the insider now owns 748,908 shares of the company’s stock, valued at $4,950,281.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 50,877 shares of company stock valued at $393,161 and have sold 8,824,625 shares valued at $54,897,886. Insiders own 21.80% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its position in shares of Amyris by 463.6% in the second quarter. Northern Trust Corp now owns 269,022 shares of the biotechnology company’s stock worth $1,719,000 after purchasing an additional 221,285 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Amyris by 87.7% in the second quarter. Bank of New York Mellon Corp now owns 106,216 shares of the biotechnology company’s stock worth $678,000 after purchasing an additional 49,628 shares during the period. B. Riley Financial Inc. boosted its position in shares of Amyris by 80.0% in the second quarter. B. Riley Financial Inc. now owns 79,219 shares of the biotechnology company’s stock worth $508,000 after purchasing an additional 35,219 shares during the period. Millennium Management LLC boosted its position in shares of Amyris by 13.5% in the second quarter. Millennium Management LLC now owns 278,748 shares of the biotechnology company’s stock worth $1,781,000 after purchasing an additional 33,085 shares during the period. Finally, Ardsley Advisory Partners boosted its position in shares of Amyris by 25.0% in the second quarter. Ardsley Advisory Partners now owns 125,000 shares of the biotechnology company’s stock worth $799,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 27.90% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Featured Story: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.